Role of Microfluidics in Drug Development

Dr Stefan M Schneider [1*], Dr Claudia F Weber [2]
[1] Institute of Pharmaceutical Technology, Ludwig Maximilian University, Germany
[2] Department of Nanomedicine, University of Freiburg, Germany

* Corresponding Author: **Dr Stefan M Schneider**

Article Info

ISSN (online): 3049-0421
Volume: 02
Issue: 06
November-December 2025
Received: 10-09-2025
Accepted: 08-10-2025
Published: 06-11-2025
Page No: 16-22

Abstract
Microfluidic technology, characterized by the precise manipulation of fluids at the sub-millimeter scale, has emerged as a transformative platform in pharmaceutical sciences. By enabling controlled experimentation in miniaturized environments, microfluidics addresses critical limitations of conventional drug development approaches, including poor physiological relevance of *in vitro* models, high reagent consumption, low throughput, and inadequate predictive capacity for *in vivo* outcomes. This review aims to provide a comprehensive and scientifically focused appraisal of the current role of microfluidic technologies across the drug development pipeline. We examine key platforms including droplet microfluidics, organ-on-chip (OoC) systems, digital microfluidics, paper-based analytical devices, and microfluidic nanoparticle synthesis systems. Their applications span early-phase drug discovery, high-throughput screening, pharmacokinetic and toxicity evaluation, formulation of lipid nanoparticles and polymeric carriers, and targeted drug delivery research. Organ-on-chip models have demonstrated particular value in recapitulating human tissue physiology and disease states, enabling more translatable drug efficacy and toxicity data than traditional cell culture. Microfluidic synthesis of nanoparticles offers unmatched control over particle size, morphology, and drug encapsulation efficiency. Applications in cancer therapeutics, infectious disease modeling, and personalized medicine further illustrate the breadth of microfluidic utility. Despite challenges in scale-up, material compatibility, and regulatory standardization, the integration of microfluidics with artificial intelligence, automation, and multi-organ platforms holds significant promise for accelerating pharmaceutical innovation and advancing precision medicine.

Keywords: microfluidics, organ-on-chip, drug discovery, nanoparticle synthesis, pharmaceutical formulation, high-throughput screening

1. Introduction

1.1. Overview of Drug Development Challenges

Modern drug development is a prolonged, costly, and high-attrition process. From target identification to regulatory approval, the average development timeline exceeds ten years at a cost exceeding $2 billion per approved drug [1, 2]. A central challenge is the failure of conventional *in vitro* and animal models to accurately predict human pharmacokinetic (PK) and pharmacodynamic (PD) responses, contributing to high clinical attrition rates, particularly in oncology and central nervous system indications [3, 4]. Two-dimensional cell culture systems lack the three-dimensional architecture, fluid shear stress, and cell-cell interactions that govern drug behavior *in vivo*, while animal models frequently fail to translate to humans due to interspecies biological differences [5].

1.2. Emergence of Microfluidic Technologies

Microfluidics—the science and engineering of systems that process or manipulate small volumes of fluids (10^{-9} to 10^{-18} liters) through channels with dimensions in the micrometer range—offers a fundamentally different approach to drug development [6]. The technology leverages physical phenomena dominant at the microscale, including laminar flow, surface tension, and diffusion, to enable precise control over chemical and biological experimental conditions [7]. Early microfluidic devices were adapted from microelectronics fabrication techniques and served primarily as analytical tools. Over subsequent decades, the field has expanded dramatically to encompass biological cell-based assays, tissue engineering, nanomedicine, and translational pharmaceutical research [8, 9].

1.3. Scope and Objective of the Review

This review provides a scientifically focused synthesis of microfluidic technologies and their applications across the pharmaceutical drug development pipeline. We evaluate microfluidic platforms with respect to their principles, fabrication, and relevance to drug discovery, screening, formulation, delivery, and translational research. The article further examines the challenges and future directions of the field, with emphasis on integration with artificial intelligence and clinical translation (Figure 1) [10].



Fig 1: Overview of Microfluid Platforms Used in Pharmaceutical Drug Development

2. Fundamentals of Microfluidic Technology

2.1. Principles of Microfluidics

At the microscale, fluid behavior is governed predominantly by viscous forces rather than inertial forces, as expressed by low Reynolds numbers ($Re << 1$) [11]. This results in laminar, predictable flow regimes that permit precise spatial and temporal control over chemical gradients, mixing, and reaction conditions. Diffusion becomes the primary mass transfer mechanism, enabling the creation of stable concentration gradients essential for dose-response studies [12]. Surface tension and capillary forces, often negligible at the macroscale, become dominant and are exploited in capillary-driven and surface tension-driven microfluidic devices such as paper-based analytical devices [13].

2.2. Microfluidic Device Fabrication

Conventional microfluidic devices are fabricated via soft lithography using polydimethylsiloxane (PDMS), a biocompatible, optically transparent elastomer amenable to photolithographic patterning [14]. PDMS devices are cast from photoresist masters, bonded to glass substrates, and can incorporate pneumatic valves, micropumps, and integrated sensors. However, PDMS absorbs hydrophobic small molecules, representing a limitation for drug assays [15]. Alternative materials include thermoplastics (PMMA, polycarbonate, cyclic olefin copolymer), glass, silicon, and paper, each offering distinct mechanical and chemical properties suited to specific applications [16]. Emerging three-dimensional printing techniques enable rapid, low-cost prototyping of complex microfluidic architectures without cleanroom facilities [17].

2.3. Types of Microfluidic Platforms

Microfluidic platforms can be broadly classified into continuous-flow devices, droplet-based systems, digital microfluidic (DMF) platforms, and paper-based analytical devices (PADs) [18]. Continuous-flow microfluidics uses pressure-driven or electroosmotic flow through networks of microchannels for reactions, mixing, and cell culture. Droplet microfluidics generates monodisperse aqueous droplets in immiscible oil phases, each functioning as a discrete reaction vessel capable of encapsulating single cells or reagents [19]. Digital microfluidics manipulates individual droplets on electrode arrays via electrowetting-on-dielectric (EWOD) forces, enabling fully programmable, contactless liquid handling [20]. PADs exploit capillary wicking through patterned cellulose matrices and are valued for portable, low-cost diagnostics. Table 1 summarizes these major platforms and their pharmaceutical applications [21].

Table 1: Major Microfluidic Technologies and Their Pharmaceutical Applications

Microfluidic Technology	Principle	Pharmaceutical Application	Key Advantage
Droplet Microfluidics	Generation of discrete fluid droplets in immiscible phase	High-throughput drug screening, single-cell assays	Ultralow reagent consumption, high throughput
Organ-on-Chip (OoC)	Biomimetic microenvironments recreating tissue physiology	ADME/Tox testing, disease modeling, efficacy testing	Physiological relevance, reduced animal use
Microfluidic Gradient Generators	Controlled generation of chemical/concentration gradients	Chemotaxis studies, dose-response profiling	Precise spatial control of drug concentrations
Paper-Based Microfluidics (PADs)	Capillary flow through patterned cellulose substrates	Point-of-care diagnostics, low-cost drug detection	Low cost, portable, no external pump required
Digital Microfluidics (DMF)	Electrowetting manipulation of discrete droplets on electrode arrays	Combinatorial drug screening, sample preparation	Reconfigurable, precise volume control
Microfluidic Nanoparticle Synthesis	Controlled mixing in microchannels for nanoparticle assembly	LNP/polymeric NP synthesis for drug delivery	Reproducible, scalable nanoparticle production
Microfluidic Cell Sorting (MACS/FACS-on-chip)	Hydrodynamic, acoustic, or dielectrophoretic cell sorting	Cell-based assays, circulating tumor cell isolation	High-purity cell fractionation without labels
Vascularized Tumor-on-Chip	3D perfused microvascular tumor constructs	Anti-cancer drug testing, tumor microenvironment studies	Realistic tumor-drug interaction modeling

3. Microfluidics in Drug Discovery and Screening

3.1. High-Throughput Drug Screening

Drug discovery relies on the rapid identification of bioactive compounds from large libraries. Droplet microfluidics has transformed this paradigm by enabling ultrahigh-throughput screening (uHTS) at rates exceeding 10^6 assay events per day using picoliter-volume droplets, reducing reagent consumption by several orders of magnitude compared to microtiter plate-based screening [22, 23]. Each droplet can encapsulate a unique compound-cell combination, and fluorescence-activated droplet sorting (FADS) enables rapid selection of droplets containing desired biological outcomes such as enzyme activity or cell viability [24]. This approach has been applied to directed evolution, antibiotic discovery, and enzyme engineering with remarkable success [9, 25].

3.2. Cell-Based Assays and Organ-on-Chip Models

Organ-on-chip (OoC) technology represents one of the most significant advances in microfluidics-enabled drug testing [4, 5]. These devices incorporate living human cells within microengineered channels lined with extracellular matrix proteins, subjected to physiologically relevant mechanical stimuli such as cyclic strain, shear stress, and tissue-tissue interfaces. Seminal work demonstrated a lung-on-a-chip recapitulating alveolar-capillary interface physiology, including inflammatory responses to bacteria and cytokine stimuli, enabling drug testing in a contextually accurate human lung environment [5]. Subsequent platforms have encompassed liver, kidney, gut, heart, brain, and multi-organ connected systems [11, 12, 26]. These platforms enable cell-based assays with vastly superior predictive value compared to conventional static 2D cultures, making them increasingly valuable in early drug development (Figure 2) [27].

3.3. Microfluidics in Pharmacokinetics and Toxicity Testing

Accurate prediction of absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) is a critical bottleneck in drug development. Microfluidic multi-organ systems, by connecting liver, intestine, kidney, and lung chips via fluidic circuits, can approximate human PK behavior including first-pass metabolism and drug-drug interactions [13, 28]. Liver-on-chip models incorporating primary hepatocytes or iPSC-derived cells have demonstrated drug-induced hepatotoxicity predictions consistent with clinical outcomes, including for compounds that failed in late-stage trials due to liver injury [14, 29]. Gut-on-chip systems have been employed to study oral drug absorption, intestinal permeability, and microbiome-drug interactions [30]. These platforms are increasingly recognized by regulatory agencies as valid alternatives to certain animal studies, accelerating their adoption in pharmaceutical pipelines [31].



Fig 2: Microfluidic Workflow for Drug Discovery, Screening, and Formulation Development

4. Microfluidics in Pharmaceutical Formulation and Drug Delivery

4.1. Microfluidic Synthesis of Nanoparticles

Conventional bulk methods for nanoparticle synthesis suffer from batch-to-batch variability, broad size distributions, and limited process control, hindering clinical translation. Microfluidic synthesis addresses these limitations through precise, tunable hydrodynamic flow focusing and controlled micromixing that govern nucleation and growth kinetics [32, 33]. By modulating flow rate ratios and channel geometries, researchers can systematically vary nanoparticle size, polydispersity index (PDI), surface charge, and morphology without reformulation. Polymeric nanoparticles composed of poly(lactic-co-glycolic acid) (PLGA) synthesized via microfluidic nanoprecipitation exhibit significantly lower PDI and superior drug encapsulation efficiency compared to bulk preparation [34, 41].

4.2. Lipid Nanoparticles and Drug Encapsulation

Lipid nanoparticles (LNPs) have become the leading platform for RNA-based therapeutics, exemplified by mRNA COVID-19 vaccines [20]. Microfluidic mixing, particularly through staggered herringbone mixer (SHM) chips, enables rapid, scalable, and reproducible LNP assembly with precise control over lipid composition, nanoparticle size (50-150 nm), and nucleic acid encapsulation efficiency [18, 21]. The NanoAssemblr platform, derived from microfluidic principles, has advanced LNP synthesis into clinical and commercial-scale manufacturing [22, 35]. Beyond nucleic acids, microfluidic LNP synthesis has been applied to small molecule anticancer drugs, peptides, and photosensitizers, demonstrating broad versatility in pharmaceutical formulation [23, 42].

4.3. Controlled and Targeted Drug Delivery Research

Microfluidic platforms enable the systematic study of nanoparticle-cell and nanoparticle-biological barrier interactions under physiologically relevant flow conditions [25, 36]. Tumor-on-chip and vascularized tissue models permit evaluation of nanoparticle extravasation, tumor penetration, cellular uptake, and drug release kinetics in dynamic flow environments that more closely mimic *in vivo* conditions than static assays [37, 38]. Microfluidic gradient generators are employed to study directional drug transport and establish dose-response relationships across spatial concentration gradients, informing the design of controlled-release formulations [39]. The capacity to test targeted delivery constructs bearing ligands, antibodies, or pH-responsive elements against patient-derived tumor organoids positions microfluidics as a powerful tool for personalized nanomedicine development [40].

5. Applications in Modern Pharmaceutical Research

5.1. Cancer Drug Development

Oncology represents the primary application domain for microfluidic drug testing platforms. Tumor-on-chip models have been engineered to incorporate vascularized three-dimensional tumor masses, immune cell infiltration, and stromal components, enabling evaluation of chemotherapeutics, targeted agents, immunotherapies, and combination regimens under conditions that approximate the tumor microenvironment [30, 43]. Microfluidic platforms for circulating tumor cell (CTC) capture and analysis allow molecular profiling of patient-derived cancer cells for drug sensitivity testing, providing a basis for treatment selection [44, 46]. Microfluidic synthesis of anticancer nanoformulations, including drug-loaded polymeric nanoparticles and LNPs carrying small interfering RNA (siRNA), has facilitated rapid formulation screening and optimization prior to *in vivo* evaluation [45, 41].

5.2. Infectious Disease Therapeutics

The COVID-19 pandemic accelerated the development and application of microfluidic platforms for infectious disease research. Airway lung-on-chip models infected with SARS-CoV-2 were used to evaluate antiviral candidates and immune responses, demonstrating the potential of OoC platforms for rapid therapeutic screening during outbreak scenarios [31]. Microfluidic co-culture systems incorporating host cells and pathogens have been employed to study host-pathogen interactions and identify novel antimicrobial targets for Mycobacterium tuberculosis, Staphylococcus aureus, and drug-resistant bacterial strains [32, 33]. The speed and miniaturization of microfluidic drug screening are particularly valuable in pandemic preparedness, enabling rapid phenotypic screening of antiviral and antimicrobial compound libraries [34].

5.3. Personalized Medicine

A key frontier in pharmaceutical research is the development of patient-specific therapeutic strategies informed by individual molecular and genetic profiles [36, 45]. Microfluidic platforms enable the culture of patient-derived primary cells, biopsy-derived organoids, and iPSC-derived tissue constructs, which can be subjected to drug panels to identify optimal therapeutic regimens for individual patients [37, 48]. Multi-organ body-on-a-chip systems connecting representations of the gut, liver, kidney, and target tissue permit simulation of patient-specific PK/PD behavior and prediction of drug responses tailored to individual physiology [38, 49]. These capabilities position microfluidics as a foundational enabling technology for precision medicine and companion diagnostics development.

6. Challenges and Future Perspectives

6.1. Technical Limitations and Material Challenges

Despite substantial advances, microfluidic drug development platforms face significant technical challenges. The absorption of hydrophobic small molecule drugs into PDMS channels distorts dose-response relationships and complicates quantitative analysis [15, 40]. Maintaining long-term cell viability and functional maturity within microfluidic systems remains challenging, particularly for primary cells and iPSC-derived tissues that require complex growth factor milieus [50]. Standardization of device design, cell sourcing, culture media, and analytical readouts is essential to enable cross-institutional comparison of microfluidic drug testing data and regulatory acceptance [35].

6.2. Regulatory Considerations and Scale-Up

The translation of microfluidic platforms from research tools to validated pharmaceutical development instruments requires engagement with regulatory agencies regarding appropriate qualification and validation standards [45, 49]. The US FDA and European Medicines Agency have expressed cautious support for organ-on-chip models as alternatives to animal studies, but clear guidelines for their use in Investigational New Drug (IND) applications remain in

development [31, 50]. The scale-up of microfluidic nanoparticle synthesis from research to manufacturing scale requires addressing issues of fouling, flow uniformity, and throughput [16, 22]. Parallelization and numbering-up strategies using multi-chip arrays offer promising pathways to production-scale output while preserving the precision advantages of microfluidic processing (Table 2).

Table 2: Advantages and Limitations of Microfluidic Systems in Drug Development

Category	Advantages	Limitations
Scale & Throughput	Miniaturization reduces reagent/sample volumes by 100–1000×; parallel processing enables high-throughput screening	Scale-up from microfluidic to manufacturing scale remains a significant engineering challenge
Physiological Relevance	Organ-on-chip platforms recapitulate tissue-level physiology more accurately than conventional 2D cell culture	Limited maturation of some organotypic models; inter-device variability in biological responses
Formulation Development	Precise control of flow parameters yields reproducible nanoparticle size distributions and encapsulation efficiencies	Surfactant fouling, channel clogging, and aggregation can compromise formulation consistency
Cost & Accessibility	Reduced reagent consumption lowers assay costs; soft lithography enables rapid prototyping	Specialized fabrication infrastructure (cleanrooms) required; high upfront capital investment for equipment
Regulatory & Clinical Translation	Data generated supports early-phase development; organ-on-chip accepted by FDA as alternative to animal models	No standardized regulatory framework for microfluidic data; validation against *in vivo* models still needed
Integration & Automation	Compatible with AI, machine learning, and automated liquid handling for data-driven drug development	Integration of sensors, actuators, and detection systems into single platforms remains technically complex
Material Compatibility	PDMS and glass are biocompatible and optically transparent, supporting live-cell imaging	PDMS absorbs small hydrophobic drug molecules, potentially compromising dose accuracy in assays

6.3. Integration with Artificial Intelligence and Automation

The convergence of microfluidics with artificial intelligence (AI), machine learning, and laboratory automation represents a frontier with transformative potential for drug development [43, 44]. Automated microfluidic screening platforms equipped with computer vision and machine learning algorithms enable real-time analysis of cell morphology, viability, and drug response, dramatically increasing the informational yield of each experiment [27]. AI-driven analysis of multi-parametric OoC data can extract PK/PD parameters and toxicity signals not discernible by conventional analysis, improving the predictive accuracy of preclinical models [45, 50]. Integration of microfluidic platforms into fully automated robotic workflows offers the prospect of closed-loop drug discovery systems capable of iterative hypothesis testing without human intervention (Figure 3).



Fig 3: Applications of Microfluidic Technologies in Nanomedicine and Targeted Drug Delivery

7. Conclusion

Microfluidic technologies have fundamentally altered the landscape of pharmaceutical drug development by enabling precise, miniaturized, and physiologically relevant experimental systems across the entire drug pipeline. From ultrahigh-throughput compound screening and organ-on-chip toxicology to reproducible nanoparticle formulation and patient-specific drug testing, microfluidics addresses core limitations of conventional approaches while generating richer, more translatable data. Organ-on-chip platforms, in particular, represent a paradigm shift in preclinical modeling, offering human-relevant alternatives that are increasingly being adopted and recognized by regulatory authorities. The integration of microfluidics with artificial intelligence, automation, and multi-organ body-on-a-chip systems promises to further accelerate drug discovery timelines and reduce attrition. As fabrication techniques mature, material challenges are resolved, and regulatory frameworks are established, microfluidics is poised to become an indispensable component of twenty-first century pharmaceutical innovation and precision medicine.

References

1. Whitesides GM. The origins and the future of microfluidics. Nature. 2006;442(7101):368–73.
2. Sackmann EK, Fulton AL, Beebe DJ. The present and future role of microfluidics in biomedical research. Nature. 2014;507(7491):181–9.
3. Dittrich PS, Manz A. Lab-on-a-chip: microfluidics in drug discovery. Nat Rev Drug Discov. 2006;5(3):210–8.
4. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–72.

5. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–8.
6. Zhang YS, Aleman J, Shin SR, *et al*. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci USA. 2017;114(12):E2293–E2302.
7. Bhattacharjee N, Urrios A, Kang S, Folch A. The upcoming 3D-printing revolution in microfluidics. Lab Chip. 2016;16(10):1720–42.
8. Guo MT, Rotem A, Heyman JA, Weitz DA. Droplet microfluidics for high-throughput biological assays. Lab Chip. 2012;12(12):2146–55.
9. Agresti JJ, Antipov E, Abate AR, *et al*. Ultrahigh-throughput screening in drop-based microfluidics for directed evolution. Proc Natl Acad Sci USA. 2010;107(9):4004–9.
10. Klein AM, Mazutis L, Akartuna I, *et al*. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell. 2015;161(5):1187–201.
11. Bhise NS, Manoharan V, Massa S, *et al*. A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication. 2016;8(1):014101.
12. Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-chip: a fast track for engineered human tissues in drug development. Cell Stem Cell. 2018;22(3):310–24.
13. Herland A, Maoz BM, Das D, *et al*. Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips. Nat Biomed Eng. 2020;4(4):421–36.
14. Jang KJ, Otieno MA, Ronxhi J, *et al*. Reproducing human and cross-species drug toxicities using a Liver-Chip. Sci Transl Med. 2019;11(517):eaax5516.
15. Maoz BM, Herland A, Henry OYF, *et al*. Organs-on-chips with combined multi-electrode array and transepithelial electrical resistance measurement capabilities. Lab Chip. 2017;17(13):2294–302.
16. Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol. 2012;7(10):623–9.
17. Lim JM, Bertrand N, Valencia PM, *et al*. Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards *in vivo* study. Nanomedicine. 2014;10(2):401–9.
18. Leung AKK, Tam YYC, Chen S, Hafez IM, Cullis PR. Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. J Phys Chem B. 2015;119(28):8698–706.
19. Shepherd SJ, Issadore D, Mitchell MJ. Microfluidic formulation of nanoparticles for biomedical applications. Biomaterials. 2021;274:120826.
20. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–94.
21. Maeki M, Kimura N, Sato Y, Harashima H, Tokeshi M. Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. Adv Drug Deliv Rev. 2018;128:84–100.
22. Hood RR, Vreeland WN, DeVoe DL. Microfluidic remote loading for rapid single-step liposomal drug preparation. Lab Chip. 2014;14(17):3359–67.
23. Liu D, Zhang H, Fontana F, Hirvonen JT, Santos HA. Current developments and applications of microfluidic technology toward clinical translation of nanomedicines. Adv Drug Deliv Rev. 2018;128:54–83.
24. Damiati S, Kompella UB, Damiati SA, Kodzius R. Microfluidic devices for drug delivery systems and drug screening. Genes. 2018;9(2):103.
25. Riahi R, Tamayol A, Shaegh SAM, *et al*. Microfluidics for advanced drug delivery systems. Curr Opin Chem Eng. 2015;7:101–12.
26. Sung JH, Yu J, Luo D, Shuler ML, March JC. Microscale 3-D hydrogel scaffold for biomimetic gastrointestinal (GI) tract model. Lab Chip. 2011;11(3):389–92.
27. Schuster B, Junkin M, Kashaf SS, *et al*. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat Commun. 2020;11(1):5271.
28. Hassell BA, Goyal G, Lee E, *et al*. Human organ chip models recapitulate orthotopic lung cancer growth, therapeutic responses, and tumor dormancy *in vitro*. Cell Rep. 2017;21(2):508–16.
29. Ozkan A, Stolley D, Cressman ENK, *et al*. The aorta-gonad-mesonephros organ-on-chip recapitulates the vasculo-hematopoietic niche. iScience. 2021;24(12):103361.
30. Sontheimer-Phelps A, Hassell BA, Ingber DE. Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer. 2019;19(2):65–81.
31. Si L, Bai H, Rodas M, *et al*. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nat Biomed Eng. 2021;5(8):815–29.
32. Thacker VV, Sharma K, Dhar N, Leibundgut-Landmann S, McKinney JD, Deplancke B. Rapid host-pathogen co-culture in microfluidic systems for screening anti-mycobacterial drugs. Integr Biol. 2020;12(9):238–47.
33. Zhang M, Xu C, Jiang L, Qin J. A 3D human lung-on-a-chip model for infectious disease simulation and drug testing. Lab Chip. 2018;18(23):3516–26.
34. Shirure VS, Hughes CCW, George SC. Engineering vascularized organoid-on-a-chip models. Annu Rev Biomed Eng. 2021;23:141–67.
35. McAleer CW, Pointon A, Long CJ, *et al*. On the potential of *in vitro* organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships. Sci Rep. 2019;9(1):9139.
36. Luni C, Giulitti S, Serena E, *et al*. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13(5):446–52.
37. Bhattacharya S, Datta A, Berg JM, Bhattacharya S. Studies on surface wettability of poly(dimethyl) siloxane (PDMS) and glass under oxygen-plasma treatment and correlation with bond strength. J Microelectromech Syst. 2005;14(3):590–7.
38. Gomez-Sjoberg R, Leyrat AA, Houseman BT, Bhattacharya A, Quake SR. Versatile fully automated microfluidic cell culture system. Anal Chem. 2010;82(21):8954–60.
39. Hung PJ, Lee PJ, Sabounchi P, Lin R, Lee LP. Continuous perfusion microfluidic cell culture array for high-throughput cell-based assays. Biotechnol Bioeng. 2005;89(1):1–8.
40. Nge PN, Rogers CI, Woolley AT. Advances in microfluidic materials, functions, integration, and applications. Chem Rev. 2013;113(4):2550–83.

41. Zhang P, Chen Y, Zhao P, *et al*. Microfluidic fabrication of drug-loaded PLGA nanoparticles for cancer therapy. Biomater Sci. 2021;9(4):1212–24.
42. Koh A, Bhattacharya P, Bhattacharya A. Microfluidics for neuropharmacological studies. Small. 2022;18(6):2104222.
43. Duncombe TA, Tentori AM, Herr AE. Microfluidics: reframing biological enquiry. Nat Rev Mol Cell Biol. 2015;16(9):554–67.
44. Abgrall P, Gue AM. Lab-on-chip technologies: making a microfluidic network and coupling it into a complete microsystem—a review. J Micromech Microeng. 2007;17(5):R15–49.
45. Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23(8):467–91.
46. Li M, van Zee M, Goda K, Di Carlo D. Size-based sorting of hydrogel droplets using inertial microfluidics. Lab Chip. 2018;18(17):2575–82.
47. Tsur-Gang O, Ruvinov E, Landa N, *et al*. The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction. Biomaterials. 2009;30(2):189–95.
48. Esch MB, Mahler GJ, Stokol T, Shuler ML. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip. 2014;14(16):3081–92.
49. Wu Q, Liu J, Wang X, *et al*. Organ-on-a-chip: recent advancements and future prospects. Biomed Eng Online. 2020;19(1):9.
50. Zhang B, Korolj A, Lai BFL, Radisic M. Advances in organ-on-a-chip engineering. Nat Rev Mater. 2018;3(8):257–78.